Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Solid Biosciences shares jumped on Wednesday after the firm provided an update from its midstage study in Duchenne muscular dystrophy.
Solid Bio shares were absolutely crushed on Tuesday after the firm announced that the FDA has placed its Ignite DMD Phase 1/2 study of SGT-001 on hold.
The top analyst upgrades, downgrades and initiations seen on Thursday included Amgen, Bank of America, Box, Chico's FAS, Microsoft, Netflix, NXP Semiconductors, StoneCo and Tiffany.
Solid Biosciences shares were crumbling on Tuesday after the firm announced its first-quarter results and an update to its midstage Duchenne muscular dystrophy trial.
Solid Bio shares were absolutely crushed on Thursday after preliminary data from the firm’s midstage trial in Duchenne muscular dystrophy was not up to par.
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Solid Biosciences watched its shares surge to kick off the week after the FDA lifted the clinical hold on its treatment for Duchenne muscular dystrophy.
Initial public offerings in the first quarter of 2018 raised more capital than in any quarter in more than three years.
Solid Biosciences Inc. (NASDAQ: SLDB) watched its shares get crushed on Thursday after the company announced some complications with the U.S. Food and Drug Administration (FDA). Specifically, the FDA...
The IPO hot streak continues this coming week with 9 offerings seeking $3.5 billion following a week when another 9 companies raised $3.6 billion.
Solid Biosciences intends to price its 7 million shares so that its initial public offering is valued up to nearly $153 million.
The 10 IPOs on the calendar for the coming week are seeking to raise a combined total of $3.1 billion, on top of a $2.4 billion capital raise from 4 IPOs last week. 2018 is off to a roaring start for...
Solid Biosciences intends to price its less than 6 million shares in the range that results in an initial public offering valued up to almost $122 million.